{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:51:40Z","timestamp":1790117500096,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.canrad.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T08:16:11Z","timestamp":1562660171000},"page":"385-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tol\u00e9rance de l\u2019irradiation st\u00e9r\u00e9otaxique hypofractionn\u00e9e des tumeurs h\u00e9patiques"],"prefix":"10.1016","volume":"23","author":[{"given":"M.","family":"Le Bon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lapeyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Belli\u00e8re-Calandry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pezet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Verrelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Beno\u00eet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2019.02.004_bib0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canrad.2010.11.003","article-title":"Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma","volume":"15","author":"Bujold","year":"2011","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.02.004_bib0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.canrad.2018.08.001","article-title":"Bases r\u00e9f\u00e9rentielles de la radioth\u00e9rapie en conditions st\u00e9r\u00e9otaxiques pour les tumeurs ou m\u00e9tastases bronchopulmonaires, h\u00e9patiques, prostatiques, des voies a\u00e9rodigestives sup\u00e9rieures, c\u00e9r\u00e9brales et osseuses","volume":"22","author":"Barillot","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.02.004_bib0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.canrad.2017.07.042","article-title":"Doses aux organes \u00e0 risque en radioth\u00e9rapie conformationnelle et en radioth\u00e9rapie st\u00e9r\u00e9otaxique\u00a0: le foie","volume":"21","author":"Debbi","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.02.004_bib0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.canrad.2017.07.040","article-title":"Radioth\u00e9rapie en conditions st\u00e9r\u00e9otaxiques des tumeurs h\u00e9patiques\u00a0: \u00e9tat de l\u2019art","volume":"21","author":"Riou","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.02.004_bib0025","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.canrad.2017.07.028","article-title":"Radioth\u00e9rapie st\u00e9r\u00e9otaxique h\u00e9patique\u00a0: organes \u00e0 risque, marges d\u2019incertitudes, doses","volume":"21","author":"Lacornerie","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.02.004_bib0030","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.canrad.2016.07.032","article-title":"D\u00e9lin\u00e9ation des organes \u00e0 risque et contraintes dosim\u00e9triques","volume":"20","author":"No\u00ebl","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.02.004_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.canrad.2016.07.055","article-title":"Mod\u00e8le pr\u00e9dictif de respect de contraintes de dose dans le foie sain en radioth\u00e9rapie st\u00e9r\u00e9otaxique h\u00e9patique","volume":"20","author":"Bednarek","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.02.004_bib0045","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.diii.2014.05.002","article-title":"Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson","volume":"95","author":"Fournier","year":"2014","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.canrad.2019.02.004_bib0050","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE).:196, 2010."},{"key":"10.1016\/j.canrad.2019.02.004_bib0055","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0060","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.02.004_bib0065","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/cncr.26404","article-title":"Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma","volume":"118","author":"Price","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.02.004_bib0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1748-717X-7-166","article-title":"Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy","volume":"7","author":"Dewas","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0075","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study","volume":"45","author":"M\u00e9ndez Romero","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0080","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","article-title":"Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"26","author":"Tse","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0085","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12094-010-0492-x","article-title":"Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma","volume":"12","author":"C\u00e1rdenes","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/1471-2407-10-475","article-title":"Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer","volume":"10","author":"Kwon","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2019.02.004_bib0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1471-2407-8-351","article-title":"Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis","volume":"8","author":"Choi","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2019.02.004_bib0100","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1002\/cncr.27533","article-title":"Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization","volume":"118","author":"Kang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.02.004_bib0105","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-015-1929-y","article-title":"The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","article-title":"Stereotactic body radiotherapy for unresectable cholangiocarcinoma","volume":"94","author":"Kopek","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0115","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2011.05.016","article-title":"Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience","volume":"99","author":"Polistina","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/0284186X.2011.652736","article-title":"Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors","volume":"51","author":"Ibarra","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1748-717X-7-67","article-title":"Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma","volume":"7","author":"Barney","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0135","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"Hoyer","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0140","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2006.10.025","article-title":"Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases","volume":"67","author":"Katz","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0150","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.02.004_bib0155","first-page":"3381","article-title":"Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results","volume":"29","author":"Ambrosino","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2019.02.004_bib0160","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1002\/cncr.25997","article-title":"Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis","volume":"117","author":"Chang","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.02.004_bib0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/030089161009600111","article-title":"Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies","volume":"96","author":"Shin","year":"2010","journal-title":"Tumori"},{"key":"10.1016\/j.canrad.2019.02.004_bib0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","article-title":"Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma","volume":"111","author":"Culleton","year":"2014","journal-title":"Radiother Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819301398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819301398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:30:28Z","timestamp":1761136228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819301398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1278321819301398"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2019.02.004","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tol\u00e9rance de l\u2019irradiation st\u00e9r\u00e9otaxique hypofractionn\u00e9e des tumeurs h\u00e9patiques","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}